Bionano Genomics (BNGO) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Business transformation and strategic focus

• Transitioning to a capital-efficient model, prioritizing recurring revenues from the installed base over global expansion.

• Emphasis on increasing utilization at 91 validated customer sites, especially in the U.S., Canada, Europe, and Israel.

• Strategic reduction in operating expenses, including headcount and R&D, to achieve cash flow breakeven within three to four years.

• Refocusing resources on profitable geographies and freezing non-essential R&D projects.

• Shift from aggressive global growth to supporting high-volume adoption and utilization at existing sites.

Product innovation and market adoption

• Launched the Stratys System, a third-generation platform with four times the throughput of its predecessor.

• VIA software, developed with NVIDIA, streamlines genome analysis and is included in a new partnership with Revvity for newborn sequencing.

• Optical genome mapping consolidates three legacy cytogenetic methods, offering faster, more actionable results at lower cost.

• The installed base grew by 30% year-over-year, with 360 systems deployed globally.

• Children's Mercy Kansas City became the first pediatric hospital to use optical genome mapping clinically.

Financial performance and guidance

• Trailing twelve months revenue reached $36.6 million, up 16% year-over-year, with Q2 revenue at $7.8 million.

• Operating expenses reduced from $134 million to $33.7 million annually through systematic cost-cutting.

• Ended the quarter with $30 million in cash and cash equivalents.

• Revised full-year revenue guidance to $32–$36 million, reflecting the new strategic focus.

• Maintaining guidance for installed systems (381–401) and Q3 revenue ($7.9–$8.9 million).